Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine

Katerina Pavenski

doi:10.1055/s-0041-1732342

TH Open, Table of Contents

CC BY 4.0 · TH Open 2021; 05(03): e335-e337
DOI: 10.1055/s-0041-1732342

Case Report

Relapse of Immune Thrombotic Thrombocytopenic Purpura Following Vaccination with COVID19 mRNA Vaccine

Katerina Pavenski

¹Department of Medicine and Laboratory Medicine, St. Michael's Hospital – Unity Health Toronto, Toronto, Canada

²Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, Canada

› Author Affiliations

Abstract

An 84 year old male with a previous history of immune thrombotic thrombocytopenic purpura (iTTP) received the first dose of COVID19 mRNA vaccine (Pfizer-Biontech). Seven days later he was diagnosed with iTTP relapse. He received in-patient treatment with therapeutic plasma exchange, high dose steroids and rituximab and subsequently recovered. This case report highlights the need to monitor patients with iTTP following vaccination.

Keywords

ADAMS/ADAMTS 13 - thrombotic thrombocytopenic purpura (TTP / HUS) - thrombocytopenia

Full Text

References

References
1 Cuker A, Cataland SR, Coppo P. et al. Redefining outcomes in immune TTP: an international working group consensus report. Blood 2021; 137 (14) 1855-1861
2 Vaccination YI, Purpura TT. Turk J Haematol 2020; 37 (03) 218-219
3 Sissa C, Al-Khaffaf A, Frattini A. et al. Relapse of thrombotic thrombocytopenic purpura after COVID-19 vaccine. Transfus Apher Sci. 2021
4 Franchini M, Liumbruno GM, Pezzo M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): Diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol 2021; ••• : Epub ahead of print
5 Yocum A, Simon EL. Thrombotic Thrombocytopenic Purpura after Ad26.COV2-S Vaccination. Am J Emerg Med 2021; S0735-6757 (21)00376-4